Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia

Key objectives of this clinical study are to:

– Determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine
– Evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine
– Evaluate different doses of IM olanzapine depot to identify the best dose(s)
– Determine the blood levels of IM olanzapine depot in patients at different points in time after an injection

Official Title

A Double-Blind, Randomized Study Comparing Instramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia

Conditions

Schizophrenic Disorders

Study Type

Interventional

Study Design

Treatment

Further Details

Study Start

Eligibility & Criteria

Inclusion Criteria:- Patients must have schizophrenia – Patients must be retrospectively judged by investigators, based on clinical interview and impression to have been stable on their antipsychotic medication (with respect to their symptoms of schizophrenia) for at least 4 weeks entry into the study – Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent – Patients must not have paticipated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry. – Female patients must not be pregnant or breast-feeding – Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia

Total Enrolment

Contact Details

“There may be multiple sites in this clinical trial.” Telephone: 1-877-CTLILLY